Evoke Pharma Future Growth
Future criteria checks 5/6
Evoke Pharma is forecast to grow earnings and revenue by 117.2% and 55% per annum respectively while EPS is expected to grow by 114.6% per annum.
Key information
117.2%
Earnings growth rate
114.6%
EPS growth rate
| Pharmaceuticals earnings growth | 21.2% |
| Revenue growth rate | 55.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 28 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 32 | 8 | N/A | N/A | 1 |
| 12/31/2025 | 20 | 1 | N/A | N/A | 1 |
| 12/31/2024 | 11 | -5 | N/A | N/A | 1 |
| 6/30/2024 | 8 | -7 | -6 | -6 | N/A |
| 3/31/2024 | 6 | -7 | -6 | -6 | N/A |
| 12/31/2023 | 5 | -8 | -5 | -5 | N/A |
| 9/30/2023 | 4 | -8 | -6 | -6 | N/A |
| 6/30/2023 | 4 | -8 | -6 | -6 | N/A |
| 3/31/2023 | 3 | -8 | -7 | -7 | N/A |
| 12/31/2022 | 3 | -8 | -7 | -7 | N/A |
| 9/30/2022 | 2 | -8 | -6 | -6 | N/A |
| 6/30/2022 | 2 | -8 | -11 | -11 | N/A |
| 3/31/2022 | 2 | -8 | -11 | -11 | N/A |
| 12/31/2021 | 2 | -9 | -12 | -12 | N/A |
| 9/30/2021 | 1 | -9 | -12 | -12 | N/A |
| 6/30/2021 | 0 | -9 | -8 | -8 | N/A |
| 3/31/2021 | 0 | -14 | -8 | -8 | N/A |
| 12/31/2020 | 0 | -13 | -7 | -7 | N/A |
| 9/30/2020 | N/A | -12 | -6 | -6 | N/A |
| 6/30/2020 | N/A | -12 | -5 | -5 | N/A |
| 3/31/2020 | N/A | -7 | -5 | -5 | N/A |
| 12/31/2019 | N/A | -7 | -6 | -6 | N/A |
| 9/30/2019 | N/A | -7 | -6 | -6 | N/A |
| 6/30/2019 | N/A | -7 | -6 | -6 | N/A |
| 3/31/2019 | N/A | -8 | -6 | -6 | N/A |
| 12/31/2018 | N/A | -8 | -7 | -7 | N/A |
| 9/30/2018 | N/A | -6 | -8 | -8 | N/A |
| 6/30/2018 | N/A | -10 | -10 | -10 | N/A |
| 3/31/2018 | N/A | -9 | N/A | -10 | N/A |
| 12/31/2017 | N/A | -12 | N/A | -9 | N/A |
| 9/30/2017 | N/A | -13 | N/A | -7 | N/A |
| 6/30/2017 | N/A | -11 | N/A | -8 | N/A |
| 3/31/2017 | N/A | -13 | N/A | -8 | N/A |
| 12/31/2016 | N/A | -11 | N/A | -9 | N/A |
| 9/30/2016 | N/A | -12 | N/A | -10 | N/A |
| 6/30/2016 | N/A | -12 | N/A | -10 | N/A |
| 3/31/2016 | N/A | -12 | N/A | -10 | N/A |
| 12/31/2015 | N/A | -12 | N/A | -10 | N/A |
| 9/30/2015 | N/A | -12 | N/A | -11 | N/A |
| 6/30/2015 | N/A | -14 | N/A | -12 | N/A |
| 3/31/2015 | N/A | -14 | N/A | -12 | N/A |
| 12/31/2014 | N/A | -13 | N/A | -12 | N/A |
| 9/30/2014 | N/A | -12 | N/A | -11 | N/A |
| 6/30/2014 | N/A | -9 | N/A | -7 | N/A |
| 3/31/2014 | N/A | -5 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EV0 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Earnings vs Market: EV0 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EV0 is expected to become profitable in the next 3 years.
Revenue vs Market: EV0's revenue (55% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: EV0's revenue (55% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EV0's Return on Equity is forecast to be high in 3 years time